请输入您要查询的百科知识:

 

词条 Trimetaphan camsilate
释义

  1. Effects

  2. Therapeutic uses

  3. References

  4. Further reading

{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 408211184
| IUPAC_name = 3,5-dibenzyl-4-oxo-8λ4-thia-3,5-diazatricyclo[6.3.0.02,6]undecan-8-ylium (7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate
| image = Trimetaphan camsilate.svg
| alt = Skeletal formulas of trimetaphan camsilate
| width = 325
| image2 = Trimetaphan camsilate 3D ball.png
| alt2 = Ball-and-stick models of the component ions of trimetaphan camsilate
| width2 = 300
| tradename = Arfonad
| pregnancy_AU =
| pregnancy_US = D
| legal_status =
| routes_of_administration = Oral, IM, IV
| bioavailability =
| metabolism =
| elimination_half-life =
| excretion = Renal, mostly unchanged
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 68-91-7
| ATC_prefix = C02
| ATC_suffix = BA01
| ATC_supplemental =
| PubChem = 23576
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB01116
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 8W556014K9
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1245
| C=22 | H=25 | N=2 | O=1 | S=1
| chemical_formula_comment = (free base)
| molecular_weight = 365.513 g/mol (free base)
}}

Trimetaphan camsilate (INN) or trimethaphan camsylate (USAN), trade name Arfonad, is a drug that counteracts cholinergic transmission at the ganglion type of nicotinic receptors of the autonomic ganglia and therefore blocks both the sympathetic nervous system and the parasympathetic nervous system. It acts as a non-depolarizing competitive antagonist at the nicotinic acetylcholine receptor, is short-acting, and is given intravenously.

Effects

Trimetaphan is a sulfonium compound and therefore carries a positive charge. Being charged, it cannot cross lipid cell membranes, such as those that comprise the blood–brain barrier. Due to this, trimethaphan does not have any effect on the central nervous system.

The ciliary muscle of the eye functions to round the lens for accommodation and is controlled mainly by parasympathetic system input. With administration of a ganglion-blocking drug, the ciliary muscle cannot contract (cycloplegia) and the patient loses the ability to focus their eyes.

Trimetaphan has a strong effect on the cardiovascular system. The size of blood vessels is primarily controlled by the sympathetic nervous system. Loss of sympathetic system input to the blood vessels causes them to get larger (vasodilation) which has the effect of lowering blood pressure. Postural hypotension is a common side effect of such drugs. Trimethaphan causes a histamine release which further lowers blood pressure. Effects on the heart include a decreased force of contraction and an increase in heart rate (tachycardia). Reflexive tachycardia can be diminished or undetected because trimetaphan is also blocking the sympathetic ganglia innervating the heart.

The motility of the gastrointestinal tract is regulated by the parasympathetic system, and blockage of this input results in diminished motility and constipation.

A rare side effect of trimethaphan administration is sudden respiratory arrest. The mechanism behind it is unknown, as trimethaphan does not appear to block neuromuscular transmission, and respiratory arrest is not an expected consequence of ganglionic blockage.[1]

Therapeutic uses

The therapeutic uses of trimetaphan are very limited due to the competition from newer drugs that are more selective in their actions and effects produced. It is occasionally used to treat a hypertensive crisis and dissecting aortic aneurysm, to treat pulmonary edema, and to reduce bleeding during neurosurgery.

References

{{Morefootnotes|article|date=September 2018}}
1. ^{{cite journal | vauthors = Dale RC, Schroeder ET | title = Respiratory paralysis during treatment of hypertension with trimethaphan camsylate | journal = Archives of Internal Medicine | volume = 136 | issue = 7 | pages = 816–8 | date = July 1976 | pmid = 938175 | doi = 10.1001/archinte.1976.03630070060018 }}

Further reading

{{refbegin}}
  • {{cite journal | vauthors = Anderson SM | title = Controlled hypotension with arfonad in paediatric surgery | journal = British Medical Journal | volume = 2 | issue = 4931 | pages = 103–4 | date = July 1955 | pmid = 14378656 | pmc = 1980290 | doi = 10.1136/bmj.2.4931.103 }}
  • {{cite journal | vauthors = Kling TF, Wilton N, Hensinger RN, Knight PR | title = The influence of trimethaphan (Arfonad)-induced hypotension with and without spine distraction on canine spinal cord blood flow | journal = Spine | volume = 11 | issue = 3 | pages = 219–24 | date = April 1986 | pmid = 3715622 | url = https://journals.lww.com/spinejournal/Abstract/1986/04000/The_Influence_of_Trimethaphan__Arfonad__Induced.7.aspx | doi = 10.1097/00007632-198604000-00007 }}
  • {{cite journal | vauthors = Moyer JH, Handley CA | title = Renal and cardiovascular hemodynamic response to ganglionic blockade with pendiomide and a comparison with hexamethonium and arfonad | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 113 | issue = 4 | pages = 383–92 | date = April 1955 | pmid = 14368507 | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=14368507 }}
  • {{cite journal | vauthors = Ulm AH | title = The treatment of primary priapism with arfonad | journal = The Journal of Urology | volume = 81 | issue = 2 | pages = 291–3 | date = February 1959 | pmid = 13631819 | doi = 10.1016/S0022-5347(17)66009-9 }}
  • {{cite journal | vauthors = Petrides G, Maneksha F, Zervas I, Carasiti I, Francis A | title = Trimethaphan (Arfonad) control of hypertension and tachycardia during electroconvulsive therapy: a double-blind study | journal = Journal of Clinical Anesthesia | volume = 8 | issue = 2 | pages = 104–9 | date = March 1996 | pmid = 8695090 | doi = 10.1016/0952-8180(95)00192-1 }}
  • {{cite journal | vauthors = Tewfik GI, Wells BG | title = The use of arfonad for the alleviation of cardio-vascular stress following electro-convulsive therapy | journal = The Journal of Mental Science | volume = 103 | issue = 432 | pages = 636–44 | date = July 1957 | pmid = 13449573 | doi = 10.1192/bjp.103.432.636 }}
  • {{cite journal | vauthors = Rowe GG, Afonso S, Lugo JE, Boake WC | title = Systemic and Coronary Hemodynamic Effects of Trimethaphan Camphorsulfonate (Arfonad) in the Dog | journal = Anesthesiology | volume = 25 | issue = 2 | pages = 156–60 | year = 1964 | pmid = 14156542 | url = http://anesthesiology.pubs.asahq.org/article.aspx?volume=25&page=156 | doi = 10.1097/00000542-196403000-00008 }}
{{refend}}{{Antihypertensives and diuretics}}{{Nicotinic acetylcholine receptor modulators}}

5 : Imidazolidinones|Nicotinic antagonists|Peripherally selective drugs|Sulfonium compounds|Ureas

随便看

 

开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。

 

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间:2024/11/10 11:40:34